Single-use systems can be a cost savings for CMOs, and these savings can be passed on to clients and, ultimately, to patients. Contract manufacturing organizations (CMOs) are on the constant lookout for better single-use systems for their clients. By a relatively wide margin, CMOs have implemented novel single-use systems sooner than therapeutic developers (innovators). This is because CMOs stay competitive when they produce biologics, particularly for R&D and clinical trials, more efficiently and cost effectively (1). For example, in BioPlan Associates’ 15th Annual Report and Survey of Biopharmaceutical Manufacturing, which included responses from 222 biopharmaceutical manufacturers and CMOs in 22 countries and 130 bioprocessing suppliers or vendors, tangential flow filtration devices are used by 94% of CMOs but only 73.9% of the biotherapeutic developers (Figure 1). Similar results are shown for novel devices such as membrane adsorbers, disposable chromatography, and perfusion devices. Click Here For Complete Article Text
|
||||||||||||||||||
| Application Sequencing | ||||||||||||||||||
|
|
||||||||||||||||||
| Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | |||||||||
|
|
|
|
|
|
|
|
|||||||||||